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1. Introduction 
1.1. c-fms and breast cancer 
In the development and progression of breast cancers, both the c-fms proto-oncogene (which 
encodes the tyrosine kinase receptor for CSF-1) as well as CSF-1 (colony stimulating factor-
1), play an important role. Evidence from transgenic models suggests that c-fms encodes for 
the sole receptor for CSF-1 (Dai et al, 2002). We and others have found that c-fms and/or CSF-
1 are expressed by the tumor epithelium in several human epithelial cancers (Kacinski et al, 
1988, 1990, 1991;  Rettenmier et al, 1989; Filderman et al, 1992; Ide et al, 2002); elevated levels 
of c-fms and CSF-1 are associated with poor prognosis (Kacinski et al, 1988;  Tang et al, 1990; 
Price et al, 1993; Chambers  et al, 1997, 2009; Scholl et al, 1993; Kluger et al, 2004; Sapi 2004). In 
human breast cancer, 94% of in situ and invasive lesions express c-fms (Kacinski et al, 1991; 
Flick et al, 1997), while 36% express both CSF-1 and c-fms (Kacinski et al, 1991; Scholl et al, 
1993). Among breast cancer patients, serum levels of CSF-1 are frequently elevated in those 
with metastases (Kacinski et al, 1991). In breast tumors, nuclear CSF-1 staining is associated 
with poor survival (Scholl et al, 1994), and c-fms expression confers an increased risk for local 
relapse (Maher et al, 1998). In a large breast cancer tissue array, c-fms (Kluger et al, 2004) is 
strongly associated with lymph node metastasis, and poor survival. This strong correlation 
with prognosis suggests an etiologic role for c-fms/CSF-1 in tumor invasion and metastasis.  
Tumor-associated macrophages bearing CSF-1 promote progression of breast cancer 
(Pollard 2004). In mice bearing human breast cancer xenografts, targeting mouse (host) c-fms 
with siRNA, or CSF-1 with antisense, siRNA or antibody suppressed primary tumor growth 
by 40-50% (Aharinejad et al, 2004; Paulus et al, 2006), and improved their survival 
(Aharinejad et al, 2004). Hence, paracrine signaling by macrophages bearing CSF-1 also 
plays a critical role in breast cancer progression. Transgenic models suggest that the absence 
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of CSF-1 results in delay of tumor invasion and metastasis, while targeting CSF-1 to 
mammary epithelium in these models enables macrophage infiltration and invasive breast 
cancer to develop and metastasize (Lin et al, 2001). 
We have reported that glucocorticoids (GC) up-regulate c-fms expression both in breast 
cancer cells (Kacinski et al, 1991; Flick et al, 2002; Sapi et al, 1995), and in primary organ 
cultures of breast cancer specimens (Kacinski et al, 2001). In a study of 329 breast cancer 
patients, 52% of the breast cancer tissues had functional glucocorticoid receptor (GR) 
(Allegra et al, 1979). This allows for breast cancer responsiveness to circulating, endogenous 
GCs.  
In the in vivo environment, with endogenous GCs, we observed extensive metastatic spread 
by breast cancer cells over-expressing c-fms, compared to controls (Toy et al, 2005). 
Parenchymal invasion was demonstrated only by the c-fms overexpressing cells. 
Interrupting the autocrine loop between c-fms and CSF-1 inhibits GC-stimulated 
invasiveness, motility, and adhesiveness in vitro of breast cancer cells (Toy et al, 2010). This 
mechanism of increasing c-fms by GC becomes aberrantly up-regulated in invasive, 
metastatic breast cancer.  
1.2. Regulation of c-fms expression 
Regulation of c-fms expression is a complex process. Both transcriptional and post-
transcriptional regulations are involved to maintain a proper level of c-fms expression. This 
chapter summarizes the research over the last 20 years concerning post-transcriptional 
regulation of c-fms and its expression in breast cancer. 
1.3. Stability of c-fms transcripts in breast cancer cells 
c-fms expression is high in metastatic breast cancer cells, but not detectable in the normal 
breast cells and non-invasive precursors of breast neoplasms (Kacinski et al, 1988, 1990). 
Unusually long half-life of c-fms mRNA partially contributes high expression in metastatic 
breast cancer cells (Chambers et al, 1994, Woo et al, 2011). GCs increase the c-fms mRNA 
half-life from 9.6 h to 18.9 h in BT20 breast cancer cells (Woo et al, 2011). In highly invasive 
MDA-MB-231 breast cancer cells, c-fms mRNA half-life increases up to 27 h in response to 
GC treatment (Figure 1). 
1.4. Post-transcriptional regulation of c-fms expression by 3’UTR 
mRNA 3’UTR contains cis-acting regulatory sequences which are involved in regulation of 
mRNA stability and polyadenylation (Mignone et al, 2003; Bashirullah et al, 2001), mRNA 
degradation (Bevilacqua et al, 2003), translation, and subcellular localization of mRNAs 
(Loya et al, 2008; Jansen, 2001). Mutations in 3’UTR could result in diseases and are 
proposed as ‘a molecular hotspot for pathology (Chen et al, 2006; Conne et al, 2000). Post-
transcriptional regulation exerted by 3’UTR is considered an important counterpart to 
transcriptional regulation for maintaining the proper level of gene products in the cell.  
 








Probe – free probe, yRNA – yeast RNA as negative control, Total RNA was isolated after dexamethasone treatment at 
the indicated time. 
Figure 1. RNase protection analysis of c-fms mRNA in MDA-MB-231 cells treated by 400 nM 
dexamethasone. 
Human c-fms mRNA 3’UTR encodes 774 nt and contains unique regions including a non-
AU-rich-69 nt sequence (3499-3567) which we have described and characterized (Woo et al, 
2009, 2011), and also several putative target sequences for miRNA binding (Figure 2). The 69 
nt sequence contains 3 islets of pyrimidine-rich sequences (CUUU). Mutations in these 
pyrimidine-rich sequences in 69 nt disrupted vigilin and HuR binding (Woo et al, 2009, 
2011). 
In metazoans, the 69 nt sequence within the 3'-UTR of c-fms mRNA is partially conserved 
between human, mouse, and rat (Figure 2). This region does not contain conventional AU-
rich elements (ARE) (Woo et al, 2009). Overall, the 69 nt sequence is slightly pyrimidine-rich 
(>57-61%) and we proposed that primary sequence as well as loop structure may be 
important for protein binding (Woo et al, 2011; Kanamori et al, 1998). Indeed, this 69 nt 
region is predicted to form a stable loop structure (Figure 3). 
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The 69 nt sequence (3499-3567) is partially conserved in human, rat, and mouse. 
Figure 2. Alignment of c-fms mRNA 3’UTRs of human, rat, and mouse. Six regions are predicted as 
targets by eight miRNAs.  
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Figure 3. RNA loops of 69 nt are predicted by mfold (http://mfold.rna.albany.edu/?q=mfold). 
1.5. microRNAs for c-fms mRNA regulation 
MicroRNAs (miRNAs) are 21-23 nucleotide single-stranded RNAs, that in general down-
regulate translation and enhance mRNA degradation (Huntzinger and Izaurralde, 2011; 
Braun et al, 2011). As a consequence, miRNAs are involved in the regulation of several 
biological functions (differentiation, hematopoiesis, tumorigenesis, apoptosis, development, 
proliferation, and growth) (Kim, 2005). They are predicted to regulate more than 60% of 
human mRNA (Friedman et al, 2009). It has been found that mRNAs with long 3’UTRs are 
more susceptible to miRNA regulation than those with short 3’UTRs as the latter lack the 
number of binding sites necessary for multiple miRNA binding and regulation (Stark et al, 
2005). 
Bioinformatics analysis predicted eight miRNAs (miR-339-5p, miR-449, miR-34, miR-610, 
miR-22, miR-134, miR-155, and miR-217) targeting six regions in c-fms mRNA 3’UTR (Figure 
2). These six target regions are also highly conserved in human, mouse and rat. Among 
those, two miRNAs (miR-610 and miR-155) were selected by us for further analysis. C-fms 
mRNA level is higher in BT20 epithelial breast cancer cells than in Hey epithelial ovarian 
cancer cells (Figure 4). In contrast, miR-610 and miR-155 RNA levels show opposite 
expression patterns with their RNA levels lower in BT20 than in Hey cells. Using a 
luciferase RNA-fused c-fms mRNA 3’UTR reporter system, introduction of miR-610 
inhibitors in BT20 cells increased luciferase RNA level by 5.5-fold and luciferase activity by 
1.3-fold. The down-regulation of mir-610 has more effects on luciferase RNA levels than 
translational repression. Some reports describe miRNA effects to be mainly on translational 
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repression, while others describe an effect primarily on mRNA decay. Guo et al (2010) 
reported that the predominant effect of mammalian miRNAs is on mRNA decay which 
results reduced translation. In contrast, in zebrafish, miR-430 reduced translation initiation 
prior to inducing mRNA decay (Bazzini et al, 2012). Djuranovic et al (2012) reported miRNA-
mediated translational repression is followed by mRNA deadenylation. Recently, the 
concept of mRNA destabilization by miRNAs gained support by genome-wide observation 
studies (Huntzinger and Izaurralde, 2011).  
 
Figure 4. (A) c-fms mRNA level is higher in BT20 than in Hey cells. (B) miR-610 RNA level is higher in 
Hey than in BT20 cells. (C) miR-155 RNA level is higher in Hey than BT20 cells. (D) Using a luciferase 
RNA-fused c-fms mRNA 3’UTR reporter system, introduction of miR-610 inhibitor increased luciferase 
RNA level by 5.5-fold and (E) luciferase activity by 1.3-fold in BT20 cells.  
1.6. RNA-binding proteins for c-fms mRNA metabolism and translation 
The first evidence supporting post-transcriptional regulation of c-fms mRNA by RNA-
binding proteins was reported in human monocytes (HL-60 cells) (Weber et al, 1989). In their 
study, TPA (12-O-tetradecanoylphorbol-13-acetate)-induced monocytic differentiation did 
not change c-fms transcription, but increased c-fms mRNA level. In addition, treatment of 
protein synthesis inhibitor cycloheximide decreased half-life of c-fms mRNA in TPA-
induced HL-60 cells. From this observation, they proposed that a labile protein(s) is 
involved in stabilization of c-fms mRNA.  
Chambers et al. (1993) reported the existence of mRNA regulatory proteins involved in c-fms 
mRNA destabilization in dexamethasone (Dex) or cyclosporin A (CsA) treated HL-60 cells. 
Dex or CsA blocked TPA-induced monocytic differentiation as well as TPA-induced 
adherence and further differentiated morphology. In TPA-induced HL-60 cells, c-fms mRNA 
half life was decreased after the addition of Dex or CsA. The effects of cycloheximide of c-
fms mRNA decay in this setting suggested the existence of labile destabilizing protein(s). 
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Furthermore, in breast carcinoma cells (BT20 and SKBR3), Dex-treatment at later time points 
increased c-fms mRNA level without affecting c-fms transcription. Addition of protein 
synthesis inhibitors prevented Dex-induced increase of c-fms mRNA level suggesting the 
presence of Dex-inducible stabilizing protein(s) in breast carcinoma cells (Chambers et al, 
1994). 
RNA-binding proteins: About 1,500 RNA-binding proteins (RBPs) have been identified, 
which bind to mRNA and modulate mRNA stability and translation. mRNA primary 
sequences as well as loop structures are known to facilitate regulatory protein binding for 
post-transcriptional regulation.  
HuR – HuR, one of the most extensively studied RBPs, encoded by ELAVL1 (embryonic 
lethal, abnormal vision, Drosophila-like 1) binds cis-acting AU-rich elements (AREs) (Barreau 
et al, 2005) and also non-ARE-containing sequences including pyrimidine-rich sequences 
(Woo et al, 2009) in target mRNAs. HuR stabilizes and increases half-life of target mRNAs 
and therefore enhances their translation (Srikantan and Gorospe, 2011). Our study indicates 
that HuR binds c-fms mRNA 3’UTR and enhances mRNA stability and translation (Woo et 
al, 2009). 
In human breast-cancer tissues, HuR is expressed mostly in nucleus (>90%), but expression 
in cytoplasm is also found. High nuclear expression of HuR is a poor prognostic factor both 
in breast and ovarian cancer (Woo et al, 2009; Yi et al, 2009).   
Vigilin – Vigilin, a high-density lipoprotein-binding protein, contains 15 K-homology (KH) 
domains (Goolsby and Shapiro, 2003). The KH domain protein family interacts with ARE-
containing mRNAs and enhances mRNA degradation and consequently down-regulates  
 
Figure 5. (A) Metabolic labeling and immunoprecipitation of CSF-1R. (B) Immunoblot of Vigilin in both 
nuclear (Nuc) and cytoplasmic (Cyto) fractions of MCF10A and MDA-MB-231BO cells. Absence of 
tubulin in nuclear fraction and presence of tubulin in cytoplasmic fraction indicate no cross-
contamination in both fractions. 
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translation (Gherzi et al, 2004). In contrast, vigilin interacts largely with unstructured 
pyrimidine-rich sequences in mRNA 3’UTR (Kanamori et al, 1998; Woo et al, 2011). We 
found that vigilin decreases c-fms mRNA half-life and down-regulates translation. Ectopic 
expression of vigilin in breast cancer cells showed that the effects of down-regulation is 
more pronounced on c-fms protein level than on the mRNA level (Woo et al, 2011). Metabolic 
labeling and immunoprecipitation of c-fms protein showed that vigilin overexpression 
down-regulated c-fms protein level in BT20 cells (Figure 5A). In contrast, suppression of 
vigilin by shRNA up-regulated c-fms protein level. 
Furthermore, immunoblot analysis showed that vigilin expression was lower in metastatic 
breast cancer MDA-MB-231BO cells than in non-tumorigenic epithelial breast MCF10A cells 
(Figure 5B). This indicates that a possible suppressive role of vigilin in invasive characters of 
breast cancer cells.  
Both in vitro and in vivo studies indicate that vigilin and HuR competitively bind to the 
pyrimidine-rich 69 nt sequence of c-fms mRNA 3’UTR (Figure 4, Woo et al, 2009, 2011). In 
vitro competition assay showed that affinity of vigilin to the 69 nt sequence is at least 3-fold 
higher than that of HuR (Figure 6).  
 
Figure 6. (A) Competition assay between vigilin and HuR by UV crosslink. (B) Co-
immunoprecipitation assay. Vigilin and HuR do not present in the same mRNP complexes. IP assays 
were carried out using cellular lysates from MDA-MB-231 cells in either RNase-free or RNase-treated 
conditions using anti-human HuR mAb, or IgG. The presence of HuR in the IP materials was monitored 
by immunoblot. H.C. – heavy chain of IgG. L.C. – Light chain of IgG. 
1.7. Effects of HuR and vigilin on invasiveness of breast cancer cells 
Increased c-fms/CSF-1 levels correlate with the invasive breast cancer phenotype, and with 
prognosis (Toy, 2005; Toy et al, 2010; Sapi, 2004; Kluger et al, 2004; Scholl et al, 1994, 1993; 
Maher et al, 1998). We studied the ability of BT20 breast cancer cells to invade through a 
human derived simple matrix in vitro. The invasion of BT20 cells was significantly inhibited 
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by the over-expression of vigilin, resulting in a 48% decrease compared to control (Figure 7). 
In contrast, over-expression of HuR increased invasiveness by 34%. Our findings suggest 
that vigilin can negatively impact, through suppression of c-fms expression, breast cancer 
cell invasiveness. In contrast, HuR enhances breast cancer cell invasiveness. 
 
Figure 7. Vigilin and HuR regulate in vitro invasiveness of BT20 breast cancer cells. This findings 
correlate with relative c-fms expression. 
1.8. Post-translational modification: dimerization and tyrosine-phosphorylation 
of CSF-1R activation of PIP3/Akt signal transduction pathway 
Activation of CSF-1R, product of the c-fms gene, requires ligand-induced non-covalent 
dimerization and phosphorylation of tyrosine residues in CSF-1R (Xiong et al, 2011; Li and 
Stanley, 1991). Here, we focus on one of the major signaling transduction pathways which 
result from CSF-1R activation. Phosphorylated CSF-1R interacts with PI3K 
(Phosphatidylinositol 3-kinases) (Shurtleff et al, 1990). In turn, PI3K converts PIP2 
(Phosphatidylinositol-3,4-bisphosphate) to PIP3 (Phosphatidylinositol-3,4,5-tisphosphate). 
PIP3 interacts with Akt (protein kinase B, PBK), and activates downstream components in 
the PIP3/Akt signaling pathway. As a result, several physiological consequences are 
regulated including cell proliferation, apoptosis, and growth. An activated PIP3/Akt 
pathway is a common event in human cancer. (Arcaro and Guerreiro, 2007). 
In breast cancer cells, multiple components are known to activate phosphorylation of CSF-
1R. Endogenous cytokine CSF-1, functioning as an autocrine signal, can bind to the 
extracellular domain of CSF-1R and activate the cytoplasmic kinase domain leading to 
autophosphorylation of tyrosine-residues in CSF-1R. There is evidence to suggest that 
endogenous CSF-1 can also bind CSF-1R without interaction on the membrane surface. 
Exogenous CSF-1, from other sources such as macrophages, osteoclasts, or fibroblasts, can 
function in a paracrine manner to activate CSF-1R on the membrane surface. Consequently, 
phosphorylation of tyrosine residues in CSF-1R activates cell proliferation and invasive 
potential (Yu et al, 2012; Sapi et al, 1996). Our study indicates glucocorticoids 
(dexamethasone) and starvation also activate CSF-1R auto-phosphorylation (Figure 8).  
CSF-1R is localized both in the cytoplasm, plasma membrane, and nuclear envelope 
(Zwaenepoel et al, 2012). CSF-1R in the nuclear envelope becomes phosphorylated in 
response to CSF-1. Phosphorylated CSF-1R in the nuclear envelope triggers the 
phosphorylation of Akt and p27 inside the nucleus. 
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Figure 8. (A) Signal transduction through pCSF-1R/PI3K regulates cell growth and angiogenesis. Both 
autocrine and paracrine signals (sCSF-1, glucocorticoids, and starvation) trigger dimerization and 
autophosphorylation of CSF-1R, which interacts with PI3K. The PI3K generates PIP3, which binds to 
Akt. Activation of PIP3/Akt activates downstream components and regulates growth, apoptosis and cell 
cycle. (B) Dexamethasone induces autophosphorylation of CSF-1R in starved MDA-MB-231 cells. 
2. Discussion 
Post-transcriptional and translational regulation of c-fms expression by vigilin and HuR 
in breast cancer cells: mRNA translation and decay are complex multi-staged processes. 
Mature mRNAs either enter translation or degradation pathways depending on the 
developmental stages of the cell. We have reported vigilin and HuR, both nuclear-
cytoplasmic shuttling RNA-binding proteins, to be involved in post-transcriptional as well 
as translational regulation of c-fms mRNA (Woo et al, 2009, 2011). Vigilin binds the 
pyrimidine-rich 69 nt sequence in the c-fms mRNA 3’UTR, to which HuR also binds. Both in 
vitro and in cell studies indicate that they compete for the same 69 nt sequence in the c-fms 
mRNA 3’UTR and that dynamic changes in the ratio of vigilin to HuR can influence their 
ability to associate with the c-fms mRNA and post-transcriptionally regulate cellular c-fms 
levels. While vigilin down-regulates c-fms translation as well as mRNA stability, HuR, in 
contrast, has opposite effect on c-fms levels; i.e., HuR up-regulates c-fms mRNA stability 
resulting increased c-fms protein levels. In our previous study, the polysome profile 
indicates vigilin is associated with free mRNPs and low MW monosomes. In contrast, HuR 
was detected with high MW polysomes (Woo et al, 2011). Vigilin also represses translation 
of reporter RNA (luciferase RNA fused with c-fms mRNA 3’UTR sequence) in the rabbit 
reticulocyte lysate cell-free translation system (Woo et al, 2011).  
Translation can be divided in three phases; initiation, elongation, and termination. 
Translation initiation is a complicated process for which a large number of eukaryotic 
initiation factors (eIFs) have been identified (Sonnenberg and Hinnebusch, 2009). 
Translation initiation starts with the assembly of a 48S quaternary initiation complex 
comprised of the 40S ribosomal subunit, eIFs, tRNAMet, and m7G cap of the mRNA.  In 
general, this 48S initiation complex scans and base pairs with the AUG initiation codon in 
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5’UTR of mRNA. This results in formation of the 80S ribosome and is continued in the 
elongation step of peptide synthesis.    
In a ‘closed-loop’ mRNP model for cap-dependent translational regulation, PABPs bind both to the 
poly A+ tail at the 3’UTR and eIF4G of the translation initiation complex at the 5’-cap 
(Huntzinger and Izaurralde, 2011). This mRNA circularization attracts ribosomes to form a 
translation initiation complex. Subsequently, after translation termination, joining of the 5’- 
and 3’-ends of the mRNA facilitates the transfer of ribosomal subunits from the 3’ to the 5’-
end.  
Our results have demonstrated presence of vigilin in free mRNP fractions in human BT20 
breast cancer cells. While vigilin association with free mRNPs may prevent ‘closed-loop’ 
formation and consequently inhibit c-fms protein translation, it was also found to associate 
with tRNAs and elongation factors (Kruse et al, 2003; Vollbrandt et al, 2004). Binding of 
vigilin with these components may deplete the available tRNAs and elongation factors for 
translation elongation. We propose a model that the impaired translation resulting from 
vigilin binding may expose both 5’- and 3’-ends of the mRNA through reduced 
circularization and increase its rate of degradation (Figure 9). In contrast, we propose that 
HuR binding to c-fms mRNA 3’UTR may enhance ‘closed-loop’ formation which increases 
the c-fms mRNA stability and also translation initiation efficiency. Immunoblot analysis 
indicates that vigilin is, in general, less expressed in breast cancer cells than in non-
tumorigenic breast cells (Woo et al, 2011). This indicates that down-regulation of vigilin may 
be partly responsible for increased c-fms level in breast cancer cells. In summary, RNA 
binding proteins, such as vigilin and HuR are critical regulators for determining the fate of 
proto-oncogene c-fms mRNA, either to be translated or decayed.  
 
Figure 9. Competition between HuR and vigilin for binding 69 nt of c-fms mRNA 3’UTR regulates 
translational machinery formation. Binding of HuR to 69 nt may induce ‘closed-loop’ formation. In 
contrast, binding of vigilin to 69 nt could prevent ‘closed-loop’ formation. 
Future research in post-transcriptional and translational regulation of c-fms in breast 
cancer: Translational inhibition and mRNA degradation are coordinated processes in which 
translation initiation is inhibited and translation factors (eIFs) are exchanged with 
repression/degradation complex (hDcp1/2, Hedls) (Fenger et al, 2005), resulting in mRNA 
degradation by exonucleases (Xrn1 and exosomes) (Balagopal and Parker, 2009). In general, 
3’-deadenylation leads to 5’-decapping followed by exonucleolytic digestion at either ends 
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of mammalian poly-A+-mRNAs (Franks and Lykke-Anderson, 2008; Zheng et al, 2008). In 
human cells, deadenylation is initiated by deadenylase complex (Pan2/3, Caf1, and Ccr4) 
(Zheng et al, 2008). Deadenylated oligo(A) mRNPs are further processed by decapping 
complex (including Xrn1 for 5’-to-3’ decay) or exosomes (for 3’-to-5’ decay). In yeast, 
decapping activators (Dhh1, Pat1, Lsm1-7, Edc1-3, Scd6) were identified which enhance 
decapping (Nissan et al, 2010). Mutated or excess nontranslating mRNAs are stored and 
degraded in processing bodies (P-bodies, GW-bodies, or Dcp-bodies) and/or stress granules 
(SGs). During inhibition of translation initiation, elevated numbers of P-bodies and SGs are 
observed (Shyu et al, 2008). Nontranslating mRNPs accumulate both in P-bodies and SGs. 
Decapping complex (hDcp1/2, Hedls) and mRNA decay fragments are found in P-bodies 
suggesting presence of 5’-to-3’ exonuclease activities (Xrn1). Deadenylation complex 
(Pan2/3, Caf1, Ccr4) is also present in mouse P-bodies. On the other hand, translation 
initiation components (eIFs) and RNA-binding proteins (Ataxin-2, Pab1, TIA-R, TIA-1) are 
found in SGs (Buchan and Parker, 2009). Another very important aspect of mRNA stability 
is mRNA binding proteins. They can stimulate decapping and degradation processes. Over-
expression of cold-inducible RNA-binding protein (CIRP), which represses translation, 
induces SGs (De Leeuw et al, 2007). In contrast, HuR was shown to release translational 
repression by helping human mRNA associated with P-bodies to re-enter polysomes 
(Bhattacharyya et al, 2006). In mammalian cells, P-bodies and SGs often dock together 
during translation inhibition. Since vigilin was shown to repress c-fms translation, it is 
crucial to understand mechanisms of transitions of c-fms mRNPs between P-bodies, SGs and 
 
Figure 10. Proposed model for post-transcriptional regulation of c-fms by HuR and vigilin. HuR 
enhances closed-loop formation and increases c-fms mRNA stability and translation. In contrast, vigilin 
prevent closed-loop formation and attracts mRNA degradation complex and down-regulates 
translation. SG – stress granule 
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polysomes. A model for these mechanisms is proposed in Figure 10. Elucidating the 
molecular mechanisms of these exchanges from one state to another is critical to the 
understanding of regulation of c-fms protein levels in breast cancer. 
3. Conclusion 
In the design of clinical therapeutics, suppression of pathogenic gene expression requires 
high specificity to prevent off-target toxicity. In order to achieve this, detailed regulatory 
mechanisms of target gene expression should be elucidated. Understanding the regulatory 
mechanisms and specific proteins through which vigilin effects translational down-
regulation of proto-oncogene c-fms in breast cancer can result in more accurate control of its 
expression. 
Based on information available from the last 20 years of research and our recent data, it is 
now possible to elucidate vigilin’s role in translational down-regulation of c-fms mRNA in 
breast cancer. Information obtained from this research will support a model on the manner 
in which interaction between a specific mRNA (c-fms) and proteins (vigilin and HuR) 
regulates c-fms at a translational level. These findings will bring us one step closer to 
development of a targeted therapy based on these mechanisms. 
4. Methods 
4.1. Cell culture 
A human breast carcinoma cell line BT20 was maintained in MEM (Sigma) supplemented 
with 0.1 mM non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 1.5 g/L 
sodium bicarbonate, and 10% fetal bovine serum (Invitrogen) in 5% CO2 at 37°C. A human 
breast carcinoma cell line MDA-MB-231 was cultured in DMEM (Sigma) supplemented with 
10% fetal bovine serum. For studies using glucocorticoids, cells were grown in starvation 
medium with 100 nM Dex (Sigma-Aldrich) for 72 h and collected for immunoblot analysis. 
A human ovarian cancer cell line Hey was grown in DMEM/F12 (Sigma) supplemented with 
10% fetal bovine serum. 
4.2. Total RNA isolation for semi-quantitative real-time RT-PCR analysis 
Cells were grown in 6-well plate for 2-3 days before harvesting. Total RNA was extracted 
with 500 ul Trizol (Invitrogen) per well. After Trizol extraction, 150 ul of supernatant was 
carefully removed to avoid genomic DNA contamination. Supernatant was re-extracted by 
equal volume of chloroform and 100 ul of supernatant was carefully removed and ethanol 
precipitated for cDNA synthesis.  
4.3. Semi-quantitative real-time RT-PCR analysis for c-fms mRNAs 
Total RNA was oligo-dT18 primed by M-MuLV reverse transcriptase (New England Biolab). 
For PCR analysis, reverse transcriptase reaction was diluted by 10-fold and 2 ul was used for 
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20 ul PCR reaction. GAPDH mRNA was amplified in PCR reaction as internal loading 
control.  
c-fms PCR primers (forward primer = 5’-GGAGTTGACGACAGGGAGTACCAC-3’, reverse 
primer = 5’- ACGAGGCCAACACCATGAGAACAG-3’).  
GAPDH PCR primers (forward primer = 5’-CGGGAAACTGTGGCGTGATGGC-3’, reverse 
primer = 5’-AGGAGACCACCTGGTGCTCAGTG-3’).  
c-fms mRNA expression level was calculated with the ∆∆CT method (Schmittgen and Livak, 
2008). 
4.4. Stem-loop real-time RT-PCR analysis for miR-610 and miR-155 
quantification 
miRNA expression was determined by the stem-loop qRT-PCR analysis to increase the 
specificity of miRNA amplification (Chen et al, 2005). cDNAs for miR-610, miR-155, and 
tRNAGlu specific were synthesized using sequence specific stem-loop forming primers. After 
10-fold dilution of reverse transcriptase reaction, 2 ul was used for 20 ul real-time PCR. 
tRNAGlu was used as internal loading control.  
miR-610 reverse transcription primer = 5’-gtcgtatccagtgcagggtccgaggtattcgcact 
ggatacgactcccag-3’) 
miR-610 PCR primers (forward primer = 5’- GGCGCTGAGCTAAATGTGTGC-3’, reverse 
primer = 5’- GTGCAGGGTCCGAGGT-3’) 
miR-155 reverse transcription primer = 5’- gtcgtatccagtgcagggtccgaggtattcgcact 
ggatacgacacccct-3’ 
miR-155 PCR primers (forward primer = 5’- GGCGCTTAATGCTAATCGTGATAG-3’, 
reverse primer = 5’- GTGCAGGGTCCGAGGT-3’) 
tRNAGlu reverse transcription primer = 5’- 
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACT GGATACGAC GGTGAAAG-3’ 
tRNAGlu PCR primers (forward primer = 5’- CTGGTTAGTACTTGGACGGGAGAC -3’, 
reverse primer = 5’- gtgcagggtccgaggt -3’) 
4.5. Analysis of c-fms mRNA Half Life 
The c-fms mRNA half-life was determined by RNase protection assay (RPA) (Bordonaro et 
al, 1994). Radioactive-labeled antisense RNA probes of c-fms mRNA was generated by in 
vitro transcription. c-fms cDNA (237nt, 1789-2025) with 67nt random sequence and 23nt T7 
promoter at 3’-end was generated by PCR and used as a templete for in vitro transcription. 
Probes with specific activity of 1x105 cpm were hybridized with 10 g of total RNA in 
hybridization buffer (80% deionized formamide, 40 mM PIPES pH6.4, 400 mM NaCl, and 1 
mM EDTA) at 42oC overnight. Next morning, unbound RNA was digested by RNase A and 
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T1 at 37oC for 1 h. After proteinase K treatment at 37oC for 30 min, samples were extracted 
by phenol-chloroform and precipitated in ethanol. Samples were analyzed on a 5% 
acrylamide/8M urea gel and exposed on X-ray film. 
4.6. Metabolic labeling and immunoprecipitation of c-fms proteins 
The BT20 cultures at 75-80% confluence were washed with PBS and incubated in labeling 
medium (Met,Cys-free RPMI1640 (Sigma R-7513), 5% dialyzed FCS, 500ug/ml Glutamine) 
for 40 min to deplete endogenous methionine and cysteine in cell. For metabolic labeling, 5 
ml labeling medium and 50 ul (500 uCi) of 35S-Methionine/35S-Cysteine per T75 flask was 
added and incubated for 30-40 min. After brief chase in chase medium (labeling medium 
with 500µg/ml Cysteine-HCl and 100µg/ml Methionine), cells were harvested and lysed in 
IP buffer (1% Triton x-100, 0.05% NP-40 in TBS, protease inhibitors). For 
immunoprecipitation of c-fms proteins, 5 ug of c-fms monoclonal antibody and 50 µl of 
Protein A/G-agarose (50% slurrry) (Santa Cruz) were added to cell lysates and incubated 
overnight at 4oC. Next morning, agarose beads was washed extensively with IP buffer and 
protein was eluted by SDS sample buffer. Labeled protein was analyzed in 10% SDS-PAGE. 
4.7. Gain-of-function and loss-of-function assay 
Plasmids encoding a control shRNA or shRNA directed against vigilin were purchased from 
Origene. The shRNAs correspond to coding region nucleotides 614–642 (5'-AAGCTCG 
GAAGGACATTGTTGCTAGACTG-3') and 829–863 (5'-CATGAAGTCTTACTCATCTCTG 
CCGAGCAGGACAA-3'), respectively, of human vigilin (GenBank BC001179). An shRNA 
containing a non-specific 29nt GFP sequence (TR30003, Origene) was used as a transfection 
control (Empty). For RNAi, 5 ×106 cells were transfected with 10 g shRNA plasmid using 
Fugene HD (Roche) according to the manufacturer's instructions. Transfected cells were 
maintained in culture medium for 3-4 days to permit knockdown before assays.   
For vigilin overexpression, pTetCMV-Fo(AS)-vigilin (Cunningham et al, 2000) was 
transfected using Fugene HD (Roche). The BT20 cells at 75-80% confluence in 6-well plates 
were transfected with 5 g of plasmids. The overexpression effects were monitored for 3-4 
days by qRT-PCR and western blot analyses.  
4.8. UV crosslinking and label transfer with c-fms mRNA 3’UTR 
UV cross-linking of HuR and vigilin was performed as described previously (Urlaub et al, 
2000) with modifications.  RNAs of c-fms 3’UTR labeled with 32P-UTP were incubated with 
recombinant HuR or recombinant vigilin proteins. The 15 l reaction mixture contained 5 
mM HEPESpH7.6, 1.25 mM MgCl2, 3.8% glycerol, 0.02 mM DTT, 1 mM EDTA, 25 mM KCl, 
50 ng yeast tRNA, 50 ng heparin, 1 mM ATP, and 32P-labeled RNA probe (50,000 cpm). After 
incubation at 30oC for 20 min, reaction mixture in a 96-well polystyrene plate on ice was 
illuminated at 254 nm, 125 mJoule for 120 seconds using a GS Gene Linker UV Chamber 
(Bio-Rad). After crosslink, excess RNA was digested by RNase A for 30 min at 37oC. 
Crosslinked protein was fractionated in 10% SDS-PAGE. 
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4.9. Invasion assay 
The Membrane Invasion Culture System (MICS chamber) was used to quantitate, the degree 
of invasion of MDA-MB-231 transiently transfected vigilin or HuR overexpressing clones. 
Breast cancer cells were cultured in the presence of 100 nM Dex and remained under starved 
conditions for transfection duration prior to the invasion assays. Parent or transfected cells, 
1x105 per well in a 6-well plate, were seeded onto 10-m pore filters coated with a human 
defined matrix containing 50 g/ml human laminin, 50 g/ml human collagen IV, and 2 
mg/ml gelatin in 10 mM acetic acid.  
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